Chemours (CC) stock surged 5.03% in early trading on Monday, following positive analyst action from RBC Capital.
The investment firm raised its price target on Chemours to $29 from $26 and maintained an Outperform rating on the shares. The upgrade followed the company's first-quarter results and signals increased confidence in the chemical company's outlook.
According to analyst data, Chemours has an average rating of overweight with a mean price target of $25.60, making RBC Capital's revised target notably more bullish than the consensus view.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments